Recruiting Heart Attack Studies in Richmond
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
Stage A: To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBC...
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in par...
Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure
Patients who have a heart attack are at high risk for future development of heart failure ('weakening of the heart'). The researchers believe that the reaction of the heart muscle to injury (inflammat...
Study to Assess SLN124 in Patients With Polycythemia Vera
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to ...
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients
This pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia. Selinexor ...
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is s...
A Study of Emapalumab for Pediatric Aplastic Anemia
The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Fundin...
About Heart Attack Clinical Trials in Richmond
A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.
There are currently 7 heart attack clinical trials recruiting participants in Richmond, VIRGINIA. These studies are seeking a combined 1,230 participants. Research is being sponsored by Cerus Corporation, AstraZeneca, Virginia Commonwealth University and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Heart Attack Clinical Trials in Richmond — FAQ
Are there heart attack clinical trials in Richmond?
Yes, there are 7 heart attack clinical trials currently recruiting in Richmond, VIRGINIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Richmond?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Richmond research site will contact you about next steps.
Are clinical trials in Richmond free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Richmond studies also compensate for your time and travel.
What heart attack treatments are being tested?
The 7 active trials in Richmond are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.
Data updated March 2, 2026 from ClinicalTrials.gov